Related Experiment Video
Updated: May 27, 2026

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
Metformin Use and Risk of Delirium in Older Adults With Type 2 Diabetes
Mingyang Sun1, Xiaoling Wang1,2, Zhongyuan Lu1,2
1Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University and Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Objective:
Delirium is a precursor and risk factor for dementia, emphasizing the urgency of effective prevention and management strategies in older adults with type 2 diabetes (T2D). Identifying long-term, safe, and effective medications to prevent diabetes-related delirium is crucial because of its significant impact on this population. This study aimed to evaluate the protective effects of metformin against delirium in older adults with T2D, using a competing risk analysis of death to provide a more accurate assessment.
Research Design And Methods:
Metformin users were compared with a cohort of nonusers. Multivariable Cox regression and Fine and Gray methods were used to assess the risk of delirium and mortality.
Results:
Our study included 66,568 metformin users and 66,568 nonusers, matched by propensity score. The use of metformin was associated with a significantly lower risk of delirium, with adjusted hazard ratios ranging from 0.77 to 0.81. A dose-response relationship was observed, indicating that higher cumulative and daily doses of metformin were associated with greater reductions in delirium risk.
Conclusions:
Metformin use is associated with a reduced risk of delirium in older adults with T2D, with higher doses offering greater protection.
Related Concept Videos
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Pharmacodynamics in Geriatric Patients: Effects of Age
Oral Hypoglycemic Agents: Biguanides and Glitazones
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

